Cargando…

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients

SIMPLE SUMMARY: Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in non-small cell lung cancer (NSCLC). A total of 172 patients with advanced NSCLC treated with osimertinib following front...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Yan-Jei, Chang, John Wen-Cheng, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Fang, Yueh-Fu, Hsu, Ping-Chih, Wu, Chiao-En
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600420/ https://www.ncbi.nlm.nih.gov/pubmed/36291877 http://dx.doi.org/10.3390/cancers14205095

Ejemplares similares

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Wang, Chin‐Chou, et al.
Publicado: (2021)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
por: Wu, Chiao-En, et al.
Publicado: (2022)

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
por: Wu, Chiao-En, et al.
Publicado: (2021)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
por: Hsu, Ping-Chih, et al.
Publicado: (2022)

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
por: Chang, John Wen-Cheng, et al.
Publicado: (2022)

Primary resistance to osimertinib despite acquired T790M
por: Chang, Ling‐Kai, et al.
Publicado: (2020)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies
por: Miura, Satoru, et al.
Publicado: (2022)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
por: Liu, Chien-Ying, et al.
Publicado: (2017)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
por: Nasu, Shingo, et al.
Publicado: (2018)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
por: Xu, Haiyan, et al.
Publicado: (2021)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Life‐threatening pneumonitis after first‐line treatment with osimertinib for primary T790M mutated non‐small cell lung cancer
por: Häntschel, Maik, et al.
Publicado: (2020)

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
por: Liao, Bin-Chi, et al.
Publicado: (2020)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
por: Peng, MuYun, et al.
Publicado: (2020)

Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
por: Buzard, Blake, et al.
Publicado: (2023)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
por: Ahn, Myung-Ju, et al.
Publicado: (2020)

Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice
por: Oh, Dong Kyu, et al.
Publicado: (2019)

Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non–Small Cell Lung Cancer
por: Li, Shan, et al.
Publicado: (2017)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
por: Gil, Hyun-Il, et al.
Publicado: (2020)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d1rgon5dqohcugb41kq9ln21pj